• Journey Medical, founded by Fortress Biotech, posted Q1 2026 revenue of USD 16 million, up 21% from USD 13.1 million year over year.
• Emrosi revenue rose to USD 6.3 million from USD 2.1 million; prescriptions reached 29,968 versus 27,023 in Q4 2025.
• Net loss narrowed to USD 2.2 million from USD 4.1 million; adjusted EBITDA turned positive at USD 0.6 million versus a loss of USD 0.9 million.
• Cash and cash equivalents increased to USD 27.2 million at March 31, 2026 from USD 24.1 million at Dec. 31, 2025.
• Emrosi secured a contract with a major US group purchasing organization, lifting commercial access coverage to about 85% of lives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fortress Biotech Inc. published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.